-
Mashup Score: 2
AUA 2021 efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, primary chemoablative therapy in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0AUA 2021: Long-Term Recurrence Free Survival Following UGN-101 Treatment for Low-Grade Upper Tract Urothelial Carcinoma - 2 year(s) ago
AUA 2021 kidney-sparing benefits, UGN-101 (JELMYTO), The OLYMPUS trial, long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term recurrence-free survival following UGN-101 treatment for low-grade #UTUC. Presentation by Karim Chamie, MD, MSHS @UclaUrology. #AUA21 written coverage by @zklaassen_md @GACancerCenter > https://t.co/k0i5mhTheB @UroGenPharma @AmerUrological @drphil_urology @urojdr https://t.co/v1Ng52LImt
-
-
Mashup Score: 3JELMYTO™ for Treating Upper Tract Urothelial Carcinoma - 2 year(s) ago
treatment of Jelmyto (mitomycin) treatment for upper tract urothelial carcinoma, ureteroscopies followed by a percutaneous resection with mitomycin induction to the upper tract, OLYMPUS trial, efficacy safety and tolerability of UGN-101 in patients with low grade noninvasive upper tract urothelial cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
JELMYTO™ for treating upper tract #UrothelialCarcinoma #UTUC. Presentation by @SimaPorten @UCSFCancer and Vitaly Margulis, MD @utsw. Written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/mJXzxlLOl5 @UroGenPharma #AUA21 @AmerUrological @SurenaMatinMD https://t.co/aGQTUsAEqL
-
-
Mashup Score: 2AUA 2021: AUA Guideline Amendment: Non-Muscle Invasive Bladder Cancer/Muscle Invasive Bladder Cancer - 2 year(s) ago
AUA 2021 AUA guidelines, guideline update for non-muscle invasive bladder cancer, AUA guidelines muscle invasive bladder cancer, high-grade T1 disease, SWOG S0337 trial, intravesical gemcitabine versus saline immediately following TURBT.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
@AmerUrological Guideline Amendment: Non-muscle invasive #BladderCancer and Muscle Invasive Bladder Cancer. Presented by @JamesJmm23 @Columbia. #AUA21 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/Sf2PPn8vZR @nyphospital https://t.co/mxwjKPzd8d
-
-
Mashup Score: 0
AUA 2021 female patients in the OLYMPUS trial, the outcomes of female patients from the OLYMPUS trial, OLYMPUS trial, patients with LG-UTUC, reverse thermal gel containing mitomycin (UGN-101 – JELMYTO® (mitomycin) upper tract urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Female patients with low-grade UTUC: primary chemoablation and durability of response in a subgroup analysis from the #OLYMPUS trial. Presented by @Dr_Jen_Linehan @ProvCalifornia. #AUA21 written coverage by @tchandra_uromd @JEFFUrology > https://t.co/qIX2XqKkyN @AmerUrological https://t.co/1bBkRIFz9k
-
-
Mashup Score: 7AUA 2021: Utility of Blue Light Flexible Cystoscopy for Bladder Cancer Surveillance after Intravesical Therapy - 2 year(s) ago
AUA 2021 blue light flexible cystoscopy (BLFC), Bacillus Calmette–Guérin (BCG) and intravesical chemotherapy, white light cystoscopy (WLC), early detection of recurrence in patients with NMIBC.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Utility of Blue-Light Flexible Cystoscopy for #BladderCancer Surveillance after Intravesical Therapy. Presentation by @SanamLadi @uscnorris. #AUA21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/8VUelVRKFm @AmerUrological @USC_Urology https://t.co/zUIctVOH9z
-
-
Mashup Score: 0A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel - 2 year(s) ago
Diane Newman is joined by J Curtis Nickel as he highlights his 2021 American Urological Association (AUA) presentation of a novel sublingual vaccine for the prevention of urinary tract infections in women. Dr. Nickels starts with a background on MV140, a self-administered submucosal vaccine. At the AUA Dr. Nickel presented the pivotal, randomized placebo-controlled trial, in which subjects were…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A novel sublingual vaccine for prevention of recurrent urinary tract infections #UTIs in women. @jcnickel4 @QueensKingston joins @DrDianeNewman @PennMedicine discussing a pivotal trial he presented at the #AUA21 annual meeting. #WatchNow > https://t.co/Y0X8JxAB5V @AmerUrological https://t.co/2ctGJl8jfr
-
-
Mashup Score: 0Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore - 2 year(s) ago
Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Delayed deterioration in patient Quality of Life, the impact of darolutamide on local symptoms in the #ARAMIS trial. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber discussing his recent #AUA21 presentation. #WatchNow > https://t.co/7M2QAWdAkc @Bayer https://t.co/dNTu2wZKaB
-
-
Mashup Score: 4
METHOD OF PARTICIPATION: Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.Estimated time to complete this…
Source: auau.auanet.orgCategories: Latest Headlines, UrologyTweet-
Live from #AUA21 Highlights in Advanced Prostate Cancer! Watch as a group of expert panelists review the latest advances in prostate cancer including the many new FDA-approved agents, as well as existing standard therapies. https://t.co/mNejQWjAE4 https://t.co/xfy0wcSAuM
-
-
Mashup Score: 0A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel - 3 year(s) ago
Diane Newman is joined by J Curtis Nickel as he highlights his 2021 American Urological Association (AUA) presentation of a novel sublingual vaccine for the prevention of urinary tract infections in women. Dr. Nickels starts with a background on MV140, a self-administered submucosal vaccine. At the AUA Dr. Nickel presented the pivotal, randomized placebo-controlled trial, in which subjects were…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
A novel sublingual vaccine for prevention of recurrent urinary tract infections #UTIs in women. @jcnickel4 @QueensKingston joins @DrDianeNewman @PennMedicine discussing a pivotal trial he presented at the #AUA21 annual meeting. #WatchNow > https://t.co/Y0X8JxAB5V @AmerUrological https://t.co/RvcJGxiqGp
-
Primary chemoablation of low-grade intermediate-risk non-muscle-invasive #BladderCancer using UGN-102, a mitomycin-containing reverse thermal gel #OPTIMAII. Presented by @UroWCH @nyulangone. #AUA21 written coverage by @WallisCJD @UofT > https://t.co/m5AIRlCcD6 @AmerUrological https://t.co/cvS96uowle